KORU Medical Systems (KRMD) Projected to Post Quarterly Earnings on Wednesday

Key Points

• KORU Medical Systems is expected to announce its Q2 2025 earnings on August 6th, with analysts predicting a loss of ($0.03) per share and revenue of $9.46 million.
• The company recently had a negative return on equity of 30.43% and a negative net margin of 15.09%, despite reporting higher revenue than expected in its last earnings release.
• Analysts currently rate KORU Medical Systems stock as a "Buy"** with a consensus target price of $4.63, although Piper Sandler has reduced their price target from $4.50 to $3.50.

KORU Medical Systems (NASDAQ:KRMD - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data before the market opens on Wednesday, August 6th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $9.46 million for the quarter. KORU Medical Systems has set its FY 2025 guidance at EPS.

KORU Medical Systems (NASDAQ:KRMD - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.03) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.01). The company had revenue of $9.64 million during the quarter, compared to analyst estimates of $8.86 million. KORU Medical Systems had a negative net margin of 15.09% and a negative return on equity of 30.43%. On average, analysts expect KORU Medical Systems to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

KORU Medical Systems Price Performance

KRMD stock traded up $0.02 during midday trading on Friday, reaching $3.48. The company had a trading volume of 145,042 shares, compared to its average volume of 129,472. The stock has a 50 day moving average price of $3.31 and a 200-day moving average price of $3.25. KORU Medical Systems has a 1-year low of $1.86 and a 1-year high of $5.05. The company has a quick ratio of 2.02, a current ratio of 2.44 and a debt-to-equity ratio of 0.01.

Analyst Upgrades and Downgrades

Separately, Piper Sandler dropped their price target on KORU Medical Systems from $4.50 to $3.50 and set a "neutral" rating for the company in a research note on Thursday, May 8th. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, KORU Medical Systems presently has an average rating of "Buy" and an average target price of $4.63.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of KRMD. Goldman Sachs Group Inc. grew its holdings in shares of KORU Medical Systems by 189.5% during the first quarter. Goldman Sachs Group Inc. now owns 242,781 shares of the company's stock worth $617,000 after purchasing an additional 158,914 shares during the last quarter. Jane Street Group LLC grew its holdings in shares of KORU Medical Systems by 136.7% during the first quarter. Jane Street Group LLC now owns 163,137 shares of the company's stock worth $414,000 after purchasing an additional 94,214 shares during the last quarter. Cubist Systematic Strategies LLC grew its holdings in shares of KORU Medical Systems by 927.4% during the first quarter. Cubist Systematic Strategies LLC now owns 77,280 shares of the company's stock worth $196,000 after purchasing an additional 69,758 shares during the last quarter. Finally, Acadian Asset Management LLC bought a new stake in shares of KORU Medical Systems during the first quarter worth about $63,000. Institutional investors own 58.60% of the company's stock.

About KORU Medical Systems

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria.